Bioniche Receives Approval For New Animal Health Product Indication
-- Enhance® will now be available in Canada --
BELLEVILLE ON, June 18, 2004 – Bioniche Life Sciences Inc., a fully-integrated human and animal biopharmaceutical company, today announced that it has received approval from the Canadian Veterinary Drugs Directorate to sell its proprietary product, Enhance®, for intra-articular injection in horses. Enhance® is used to treat synovitis and/or osteoarthrosis. It is the Company’s intent to register these claims in other jurisdictions as well.
“We are very pleased to receive this approval from the Veterinary Drugs Directorate,” said Rick Culbert, President of Bioniche Animal Health Canada, a Division of Bioniche Life Sciences Inc. “Enhance® has been a very successful product for us in Australia, and we look forward to making it available to our Canadian veterinary customers.”
Enhance® is a sterile sodium hyaluronate solution, obtained from a selective fermentation source using a manufacturing process that is free from thermal degrading effects. The manufacturing occurs at a Bioniche owned and operated facility in Galway, Ireland.
“It is gratifying to be able to offer one more product to veterinarians in Canada,” added Graeme McRae, President & CEO of Bioniche Life Sciences Inc., “particularly one that has been developed by Bioniche and manufactured to our consistently high standards by our staff in Ireland.”